surpass-cvot tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full trial results: https://nej.md/4qd5rLx Comparison of tirzepatide and dulaglutide

It has undergone clinical trials to establish its safety and efficacy for the indicated use

Lichen planus and lichen planus pigmentosus following gold therapycase reports and review of the literatureZ Hautkr

Similar studies using basal insulin and GLP-1 receptor antagonists produced statistically significant HbA1c control and body weight reduction, but no alteration in gastric side effects

Where competitors escalate to $449 or more at 15 mg, Mochi stays at $278

Drawing 50 units for a 2.5mg dose is very easy to measure accurately

Insurance Coverage: Some insurance plans covered Mounjaro for diabetes but not Zepbound for weight loss, leading doctors to prescribe Mounjaro off-label